Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1799491

CSCC[C@H](N)C(N)=O.Cl

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RNPEP Q9H4A4 1/20 0.43
ANPEP P15144 1/20 0.41
ENPEP Q07075 1/20 0.41
NOS2 P35228 3/20 0.38
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
BHMT Q93088 4/20 0.37
BHMT2 Q9H2M3 1/20 0.37
METAP2 P50579 1/20 0.35
METAP1 P53582 1/20 0.35
CYP2C19 P33261 1/20 0.34
THPO P40225 1/20 0.34
CTSC P53634 1/20 0.34
TSHR P16473 1/20 0.33
FOLH1 Q04609 1/20 0.33
ARG1 P05089 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
PGGT1B P53609 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2026581 1.00 RNPEP (0.43) RNPEPANPEPENPEPNOS2NOS3
SCHEMBL358438 0.98
SCHEMBL9223289 0.98 RNPEP (0.45) RNPEPANPEPENPEPNOS2NOS3
SCHEMBL1416384 0.98
SCHEMBL3316021 0.98
SCHEMBL27539386 0.95 RNPEP (0.43) RNPEPANPEPENPEPNOS2NOS3
Acetic Acid SCHEMBL10586329 0.91 RNPEP (0.45) RNPEPANPEPENPEPNOS2NOS3
Acetic Acid SCHEMBL10586335 0.91 RNPEP (0.45) RNPEPANPEPENPEPNOS2NOS3
Trifluoroacetic Acid SCHEMBL6557109 0.85 RNPEP (0.40) RNPEPANPEPENPEPNOS2NOS3
Trifluoroacetic Acid SCHEMBL6557113 0.85 RNPEP (0.40) RNPEPANPEPENPEPNOS2NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180070612-A1 RUMEN BY-PASS ANIMAL FEED COMPOSITION AND METHOD OF MAKING SAME WAN FENG (US) 2018-03-15 US claimed
CN-107708432-A Rumen bypass animal feed composition and preparation method thereof 拜内梅尔克公司 2018-02-16 CN claimed
JP-63183550-A None JP disclosed
US-20260027071-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) 2026-01-29 US disclosed
EP-4561555-A2 PLATINUM COMPLEXES, RELATED COMPOSITIONS, AND USES THEREOF IN CYANIDE COUNTERMEASURES Purdue Research Foundation (US) 2025-06-04 EP disclosed
EP-4483868-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID Boo, Yong Chool (KR) 2025-01-01 EP disclosed
WO-2024026123-A2 PLATINUM COMPLEXES, RELATED COMPOSITIONS, AND USES THEREOF IN CYANIDE COUNTERMEASURES PURDUE RESEARCH FOUNDATION (US) 2024-02-01 WO disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023158164-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID 경북대학교 산학협력단 2023-08-24 WO disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-31 US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed
JP-S63183550-A RACEMIZATION OF OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE NITTO CHEM IND CO LTD 1988-07-28 JP disclosed
US-4680283-A LACHRYMATORS MERCK & CO., INC. (US) 1987-07-14 US disclosed
EP-0176436-A2 Analogs of substance P and eledoisin MERCK & CO. INC. (US) 1986-04-02 EP disclosed
US-4452814-A ANTITUMOR AGENTS SUAMI T (JP) 1984-06-05 US disclosed
US-4350628-A OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE RESEARCH CORPORATION (US) 1982-09-21 US disclosed
US-4283328-A TREATING AN N-BLOCKED AMINO ACID RESIDUE WITH A TETRAMETHYL GUANIDINIUM SALT OF A PEPTIDE CHAIN RESEARCH CORPORATION (US) 1981-08-11 US disclosed
US-4261884-A DESIRABLE BIOLOGICAL PROPERTIES AND STABILITY TO ENZYME CLEAVAGE RESEARCH CORPORATION (US) 1981-04-14 US disclosed
EP-0010830-A2 Dehydropeptides Research Corporation (US) 1980-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027071-A1 COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION COMPRISING AMIDATED AMINO ACID COL2A1, COL14A1, GLS RNPEP 95/4885ANPEP 15/4885ENPEP 14/4885
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CD44, DAO, FUT6 RNPEP 304/4885ANPEP 139/4885ENPEP 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.